These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33750285)

  • 1. Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment.
    Biondi BE; Frank CA; Forray A; Springer SA
    Subst Abus; 2021; 42(4):905-911. PubMed ID: 33750285
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.
    Springer SA; Brown SE; Di Paola A; Altice FL
    Drug Alcohol Depend; 2015 Dec; 157():158-65. PubMed ID: 26560326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.
    Soares WE; Wilson D; Gordon MS; Lee JD; Nunes EV; O'Brien CP; Shroff M; Friedmann PD
    Drug Alcohol Depend; 2019 Jan; 194():482-486. PubMed ID: 30522048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.
    Springer SA; Di Paola A; Azar MM; Barbour R; Biondi BE; Desabrais M; Lincoln T; Skiest DJ; Altice FL
    J Acquir Immune Defic Syndr; 2018 May; 78(1):43-53. PubMed ID: 29373393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.
    Korthuis PT; Lum PJ; Vergara-Rodriguez P; Ahamad K; Wood E; Kunkel LE; Oden NL; Lindblad R; Sorensen JL; Arenas V; Ha D; Mandler RN; McCarty D;
    Addiction; 2017 Jun; 112(6):1036-1044. PubMed ID: 28061017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.
    Di Paola A; Lincoln T; Skiest DJ; Desabrais M; Altice FL; Springer SA
    Contemp Clin Trials; 2014 Nov; 39(2):256-68. PubMed ID: 25240704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS).
    Waddell EN; Springer SA; Marsch LA; Farabee D; Schwartz RP; Nyaku A; Reeves R; Goldfeld K; McDonald RD; Malone M; Cheng A; Saunders EC; Monico L; Gryczynski J; Bell K; Harding K; Violette S; Groblewski T; Martin W; Talon K; Beckwith N; Suchocki A; Torralva R; Wisdom JP; Lee JD
    J Subst Abuse Treat; 2021 Sep; 128():108389. PubMed ID: 33865691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
    Murphy SM; Jeng PJ; Poole SA; Jalali A; Vocci FJ; Gordon MS; Woody GE; Polsky D
    Addict Sci Clin Pract; 2020 Apr; 15(1):15. PubMed ID: 32321570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.
    Lier AJ; Seval N; Vander Wyk B; Di Paola A; Springer SA
    J Subst Abuse Treat; 2022 Nov; 142():108852. PubMed ID: 35988513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.
    Lee JD; Friedmann PD; Boney TY; Hoskinson RA; McDonald R; Gordon M; Fishman M; Chen DT; Bonnie RJ; Kinlock TW; Nunes EV; Cornish JW; O'Brien CP
    Contemp Clin Trials; 2015 Mar; 41():110-7. PubMed ID: 25602580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.
    Farabee D; Condon T; Hallgren KA; McCrady B
    J Subst Abuse Treat; 2020 Oct; 117():108076. PubMed ID: 32811623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.
    Jalali A; Jeng PJ; Polsky D; Poole S; Ku YC; Woody GE; Murphy SM
    J Subst Abuse Treat; 2022 Oct; 141():108835. PubMed ID: 35933942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.
    Springer SA; Di Paola A; Azar MM; Barbour R; Krishnan A; Altice FL
    Drug Alcohol Depend; 2017 May; 174():158-170. PubMed ID: 28334661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis.
    Hoffman KA; Baker R; Fanucchi LC; Lum PJ; Kunkel LE; Ponce Terashima J; McCarty D; Jacobs P; Korthuis PT
    Addict Sci Clin Pract; 2021 Nov; 16(1):67. PubMed ID: 34758887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
    Korthuis PT; Cook RR; Lum PJ; Waddell EN; Tookes H; Vergara-Rodriguez P; Kunkel LE; Lucas GM; Rodriguez AE; Bielavitz S; Fanucchi LC; Hoffman KA; Bachrach K; Payne EH; Collins JA; Matthews A; Oden N; Jacobs P; Jelstrom E; Sorensen JL; McCarty D
    Addiction; 2022 Jul; 117(7):1961-1971. PubMed ID: 35129242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
    Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
    Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community.
    Springer SA; Altice FL; Herme M; Di Paola A
    Contemp Clin Trials; 2014 Mar; 37(2):209-18. PubMed ID: 24384538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release naltrexone opioid treatment at jail reentry (XOR).
    McDonald RD; Tofighi B; Laska E; Goldfeld K; Bonilla W; Flannery M; Santana-Correa N; Johnson CW; Leibowitz N; Rotrosen J; Gourevitch MN; Lee JD
    Contemp Clin Trials; 2016 Jul; 49():57-64. PubMed ID: 27178765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis.
    Bahji A; Carlone D; Altomare J
    Addiction; 2020 Aug; 115(8):1413-1425. PubMed ID: 31863669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study.
    Brenna IH; Marciuch A; Birkeland B; Veseth M; Røstad B; Løberg EM; Solli KK; Tanum L; Weimand B
    J Subst Abuse Treat; 2022 May; 136():108667. PubMed ID: 34865937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.